Anticoagulant Reversal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Anticoagulant Reversal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

1
1

Bleeding complications is a common concern associated with the use of anticoagulation drugs. Anticoagulant reversal drugs act as antidote agents to neutralize the condition that involves bleeding complications; for example, an unplanned surgery, hemophilia, etc. Anticoagulation reversal drugs are also required to support the medical treatment for prevention and reduction of recurrent deep-vein venous thromboembolism (VTE). These drugs reduce the incidence of recurrent ischemic events in patients with coronary syndrome. Anticoagulant reversal drugs such as idarucizumab contain selective monoclonal antibodies which have high binding affinity and which act as an antidote to dabigatran. This also helps in the prevention of stroke in patients with non-valvular atrial fibrillation. Heparin overdose, hypoprothrombinemia, reversal of acquired coagulation factor deficiency, reversal of dabigatran anticoagulation and vitamin K deficiency are a few medical conditions associated with anticoagulant reversal drugs.

Rise in the prevalence of gastrointestinal bleeding and platelet disorders is one of the major factors propelling the anticoagulant reversal drugs market. Moreover, several medical journals reveal that 1%–5% of patients taking factor Xa-inhibitors may experience spontaneous bleeding. This is one of the key factors driving the global anticoagulant reversal drugs market. However, certain limitations associated with these drugs such as contraindication in patients with severe renal or hepatic diseases and absence of specific reversal drugs are likely to hamper the anticoagulant reversal drugs market in the next few years.

Based on drug type, the global anticoagulant reversal drugs market can be segmented into vitamin K, idrucizumab, tranexamic acid, prothrombin complex concentrates, and others. The idrucizumab segment is likely to expand at a rapid pace during the forecast period. This can be attributed to increase in the incidence of gastrointestinal bleeding among geriatric population led by increase in the use of pradaxa (a kind of drug that acts as an anticoagulant agent). In terms of distribution channel, the market can be categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is likely to expand at a rapid pace during the forecast period, as several unplanned surgeries such as those in case of accident cases are performed in hospitals.

In terms of region, the global anticoagulant reversal drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Rise in the incidence of von Willebrand disease (the most common inherited bleeding disorder caused by clotting proteins) in North America is the major factor driving the anticoagulant reversal drugs market in the region. Increase in the demand for the treatment of hemophilia and growing awareness about the effect of constant use of anticoagulant drugs (blood-thinner drugs) are likely to propel the market in Europe. Rise in the demand for therapies effective in reducing complications associated with blood disorders and increase in the prevalence of hemophilia in the region are major factors that drive the anticoagulant reversal drugs market in Asia Pacific. The insufficiency of vitamin K is most common among mothers and newborn babies, which leads to vitamin K deficiency bleeding, especially in countries of East Africa such as Uganda. The prevalence of insufficiency of vitamin K is increasing, which is one of the most important factors expected to boost the anticoagulant reversal drugs market in Middle East & Africa during the forecast period.

Key players operating in the global anticoagulant reversal drugs market are Boehringer Ingelheim Pharmaceuticals Inc., Valeant Pharmaceuticals International, Inc., Fresenius Kabi USA, and CSL Behring.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074